Respiratory syncytial virus infections: characteristics and treatment (Q36301717)

13 August 2017

1 reference

title

Respiratory syncytial virus infections: characteristics and treatment (English)

1 reference

13 August 2017

Sharon M Chidgey

1

1 reference

PubMed ID

16259768

13 August 2017

Kenneth J Broadley

series ordinal

2

1 reference

13 August 2017

1 November 2005

1 reference

Journal of Pharmacy and Pharmacology

13 August 2017

1 reference

13 August 2017

57

1 reference

13 August 2017

11

1 reference

13 August 2017

1371-1381

1 reference

Short term effects of adrenaline in bronchiolitis: a randomised controlled trial

13 August 2017

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

The pharmacologic mechanism by which inhaled epinephrine reduces airway obstruction in respiratory syncytial virus-associated bronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

Ribavirin aerosol for acute bronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

Efficacy of nebulized epinephrine versus salbutamol in hospitalized infants with bronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

Effectiveness of drug therapies to treat or prevent respiratory syncytial virus infection-related morbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

A randomized, double-blind, placebo-controlled trial of dexamethasone in severe respiratory syncytial virus (RSV) infection: effects on RSV quantity and clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

Prednisolone treatment of respiratory syncytial virus infection: a randomized controlled trial of 147 infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

Respiratory syncytial virus infection in high risk infants and the potential impact of prophylaxis in a United Kingdom cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

Surfactant abnormalities in infants with severe viral bronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

Respiratory syncytial virus bronchiolitis: a double-blind dexamethasone efficacy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

Randomised controlled trial of budesonide for the prevention of post-bronchiolitis wheezing

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

Antibiotic treatment of pneumonia and bronchiolitis. A prospective randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

Helium-oxygen mixture does not improve gas exchange in mechanically ventilated children with bronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

Nosocomial respiratory syncytial virus infections: the "Cold War" has not ended

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

Modes of transmission of respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

Respiratory syncytial virus infections in infants: Quantitation and duration of shedding

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

Epinephrine for bronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

Treatment of respiratory failure with inhaled nitric oxide and high- frequency ventilation in an infant with respiratory syncytial virus pneumonia and bronchopulmonary dysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

The fusion glycoproteins of human respiratory syncytial virus of subgroups A and B: sequence conservation provides a structural basis for antigenic relatedness

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

The two amino acid substitutions in the L protein of cpts530/1009, a live-attenuated respiratory syncytial virus candidate vaccine, are independent temperature-sensitive and attenuation mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

Inhaled nitric oxide for a severe respiratory syncytial virus infection in an infant with bronchopulmonary dysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

Demonstration that glycoprotein G is the attachment protein of respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

Risk of serious bacterial infection in young febrile infants with respiratory syncytial virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

New drugs and treatment for respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

Nebulized 3% hypertonic saline solution treatment in hospitalized infants with viral bronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

Heliox therapy in infants with acute bronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

Nosocomial respiratory syncytial virus infections: the cost-effectiveness and cost-benefit of infection control

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

Variation in severity of respiratory syncytial virus infections with subtype

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

Respiratory syncytial virus: recent progress towards the discovery of effective prophylactic and therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

Economic impact of viral respiratory disease in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

Efficacy of recombinant human deoxyribonuclease I in the hospital management of respiratory syncytial virus bronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

Effect of inhaled nitric oxide on respiratory mechanics in ventilated infants with RSV bronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

The immunogenicity, protective efficacy and safety of BBG2Na, a subunit respiratory syncytial virus (RSV) vaccine candidate, against RSV-B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

Efficacy and safety studies of a recombinant chimeric respiratory syncytial virus FG glycoprotein vaccine in cotton rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

Management of acute bronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

Bronchiolitis-associated hospitalizations among US children, 1980-1996.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

Novel pathways in the pathogenesis of respiratory syncytial virus disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

Randomised double blind placebo controlled trial of prednisolone in children admitted to hospital with respiratory syncytial virus bronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

Dexamethasone for treatment of patients mechanically ventilated for lower respiratory tract infection caused by respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

Severity of respiratory syncytial virus infection is related to virus strain

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2FJPP.57.11.0001

21 January 2018

Identifiers

DOI

10.1211/JPP.57.11.0001

1 reference

13 August 2017

1 reference

PubMed ID

16259768